A presentation on thimerosal, a mercury-based vaccine preservative, set to be delivered to the CDC’s advisory committee has come under scrutiny for referencing a non-existent study. The report, “Thimerosal as a Vaccine Preservative,” authored by Lyn Redwood—former leader of the anti-vaccine group Children’s Health Defense—cited a 2008 study allegedly co-authored by UC Davis Professor Emeritus Robert Berman. However, Berman confirmed that such a study was never conducted by him and said the cited findings misrepresented his actual research published in Toxicological Sciences.
The erroneous citation was first reported by Reuters, prompting the CDC to upload a revised version of Redwood’s presentation, removing the disputed slide. The controversy has intensified after Health Secretary Robert F. Kennedy Jr. recently replaced the CDC’s entire 17-member vaccine panel with eight new members, half of whom are known vaccine skeptics.
Both Republican Senator Bill Cassidy and Democratic Senator Patty Murray have urged postponement of the June 25–26 meeting, citing the panel’s lack of vetting and the absence of a CDC director. Redwood’s presentation contrasts with a separate CDC staff report reaffirming that thimerosal-containing vaccines do not cause autism or other neurodevelopmental issues.
According to CDC data, 96% of flu vaccines administered during the 2024–25 season were thimerosal-free, and only 0.3% of flu vaccines given to pregnant women contained the preservative. Kennedy, a long-time critic of vaccine safety, has previously claimed thimerosal causes brain damage—claims consistently debunked by scientific research.
The thimerosal debate highlights rising tensions around vaccine policy and misinformation, especially as newly appointed CDC advisors consider whether to recommend thimerosal-free vaccines for all pregnant women and children. Redwood has not yet responded to requests for comment.


Trump Endorses Japan’s Sanae Takaichi Ahead of Crucial Election Amid Market and China Tensions
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options
Trump Lifts 25% Tariff on Indian Goods in Strategic U.S.–India Trade and Energy Deal
SpaceX Starship Explodes in Texas During Test, Citing Nitrogen Tank Failure
Marco Rubio Steps Down as Acting U.S. Archivist Amid Federal Law Limits
FDA Lifts REMS Requirement for CAR-T Cell Cancer Therapies
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
NASA and Roscosmos Chiefs Meet in Florida to Discuss Moon and ISS Cooperation
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 



